Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience

Background: We assessed the efficacy and safety of sunitinib as the first-line treatment in metastatic renal cell carcinoma (mRCC) patients. The predictors of survival and efficacy in mRCC as identified from previous studies, including the Memorial Sloan Kettering Cancer Center (MSKCC) and the Inter...

Full description

Bibliographic Details
Main Authors:	Ong, Teng Aik, Abd Ghafar, Nahjatul Kursyiah, Alip, Adlinda, Yap, Ning Yi, Saad, Marniza
Format:	Article
Published:	Medknow Publications 2018
Subjects:	R Medicine

Similar Items

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
by: Krastan B. Blagoev, et al.
Published: (2013-02-01)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01)

Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib
by: Leonardo Gomes da Fonseca, et al.
Published: (2014-04-01)

Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma
by: Filipa Amaro, et al.
Published: (2022-04-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
by: Marija Kraljević, et al.
Published: (2023-01-01)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
by: Jingyang Lin, et al.
Published: (2023-01-01)

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
by: Celia Prior, et al.
Published: (2014-01-01)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
by: Magnus Lindskog, et al.
Published: (2022-06-01)

Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report
by: Robert Šeparović, et al.
Published: (2018-01-01)

A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma
by: Dylan B. Ness, et al.
Published: (2023-06-01)

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
by: Bernard Paule, et al.
Published: (2010-05-01)

Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients
by: Simon Matoori, et al.
Published: (2017-08-01)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
by: Touplikioti Panagiota, et al.
Published: (2009-03-01)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
by: Zeshen Wu, et al.
Published: (2022-10-01)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
by: Predrag Nikic, et al.
Published: (2022-06-01)

Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma
by: Miki Takenaka Sato, et al.
Published: (2022-11-01)

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia
by: Teng Aik Ong, et al.
Published: (2023-01-01)

In vivo effects of sirolimus and sunitinib of breast cancer prognostic markers
by: Jaffar, Nurul Fathiyatul Nabila
Published: (2020)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
by: Jeannine Witte, et al.
Published: (2018-09-01)

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review
by: Zhixiang Gao, et al.
Published: (2024-05-01)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-03-01)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2019-03-01)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
by: Kaamar Azijli, et al.
Published: (2016-01-01)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
by: Stefan Küffer, et al.
Published: (2022-09-01)

Visceral Adiposity as a Significant Predictor of Sunitinib-Induced Dose-Limiting Toxicities and Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
by: Jee Soo Park, et al.
Published: (2020-12-01)

Efficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens
by: K. V. Menshikov, et al.
Published: (2022-06-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Establishment of epithelial and fibroblast cell cultures and cell lines from primary renal cancer nephrectomies
by: Yap, Ning Yi, et al.
Published: (2019)

An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.
by: Pwint, T, et al.
Published: (2011)

An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib
by: Pwint, T, et al.
Published: (2011)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
by: Igor Tsaur, et al.
Published: (2022-09-01)

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
by: Ondrej Fiala, et al.
Published: (2020-03-01)

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
by: Yoshifumi Kadono, et al.
Published: (2023-05-01)

The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy in an Asian setting
by: Saad, Marniza, et al.
Published: (2018)

Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report
by: Maria Massucci, et al.
Published: (2021-01-01)